Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

ProMetic Announces the Exercise of the Over-Allotment Option Under Its Bought Deal Offering of Common Shares

Marketwired May 26, 2015

ProMetic Provides Update on PBI-4050 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")

Marketwired May 20, 2015

ProMetic Enters Into Strategic Long-Term Manufacturing Agreement With Emergent BioSolutions

Marketwired May 19, 2015

ProMetic Reports its 2015 Annual and Special Meeting of Shareholders Highlights

Marketwired May 13, 2015

ProMetic Reports Its First Quarter 2015 Highlights and Financial Results

Marketwired May 13, 2015

ProMetic to Develop C1 Esterase Inhibitor (C1-INH) as Its Next Plasma-Derived Drug Candidate

Marketwired May 7, 2015

ProMetic Announces Closing of $50 M Bought Deal Offering of Common Shares

Marketwired May 6, 2015

ProMetic Announces $50 Million Bought Deal Offering to Fund Strategic Growth Initiatives

Canada NewsWire April 14, 2015

ProMetic Reports Its 2014 Fourth Quarter and Year End Highlights and Financial Results

Marketwired March 31, 2015

ProMetic to Report Its Fourth Quarter and Year End 2014 Financial Results and Hold Conference Call/Webcast

Marketwired March 30, 2015

ProMetic Successfully Completes Its PBI-4050 Phase Ib in Patients With Chronic Kidney Disease ("CKD")

Marketwired March 19, 2015

ProMetic Announces Its Inclusion to the S&P/TSX Composite Index

Marketwired March 16, 2015

IIROC Trade Resumption - ProMetic Life Sciences Inc.

Newsfile February 17, 2015

IIROC Trade Resumption - LIM; PLI

Canada NewsWire February 17, 2015

US FDA Grants Orphan Drug Designation to ProMetic's PBI-4050 Drug for the Treatment of Idiopathic Pulmonary Fibrosis

Marketwired February 17, 2015

IIROC Trading Halt - PLI

Canada NewsWire February 13, 2015

ProMetic Receives $11.4 Million Purchase Order from Multinational Client

Marketwired February 12, 2015

ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients With Idiopathic Pulmonary Fibrosis

Marketwired February 4, 2015

ProMetic's PBI-4050 Cleared to Commence Clinical Trials in Patients with Metabolic Syndrome and Associated Type 2 Diabetes

Marketwired January 26, 2015

ProMetic Provides Q4 2014 Clinical Development and Commercial Milestones Update

Marketwired January 6, 2015